Abstract
BackgroundTo investigate the effect of albumin infusion in cirrhotic patients admitted for acute gastrointestinal bleeding.MethodsMedical records of cirrhotic patients who admitted due to acute gastrointestinal bleeding through January 2009 to December 2018 were systemically reviewed. Clinical data and the total amount of albumin and red blood cell used during hospitalization were recorded. For patients with rebleeding, the amount of albumin and red blood cell used before rebleeding was also documented. The primary outcome was the occurrence of rebleeding and the second outcome was in-hospital mortality. Univariate and multivariate logistic analysis were performed to identify risk factors associated with rebleeding and in-hospital mortality.ResultsA total of 2239 cirrhotic patients were included in the analysis. There were 245 episodes of in-patient rebleeding occurred, while 135 patients died. Overall, more red blood cells and albumin were prescribed to patients who suffered rebleeding. In terms of the amount before rebleeding, the red blood cell was higher in patients with rebleeding, but the albumin infusion were similar. In the multivariate model, the albumin infusion was an independent risk factor associated with rebleeding (adjusted OR for ≤40g, 0.385 [0.252-0.588], p<0.001; OR for >40g, 0.295 [0.169-0.514], p<0.001). The use of albumin more than 40g during hospitalization reduces the risk of in-patient mortality (adjusted OR for ≤40g, 0.730 [0.375-1.423], p=0.356; OR for >40g, 0.389 [0.180-0.838], p=0.016).ConclusionsAlbumin infusion could reduce risk of in-hospital rebleeding. Moreover, more than 40g albumin infusion decrease numbers of mortality in cirrhosis admitted for acute gastrointestinal bleeding.
468: TIMELY ALBUMIN INFUSION IS ASSOCIATED WITH A SHORTER HOSPITALIZATION IN CIRRHOTIC PATIENTS
